Fig. 6
The kinetics of VCN and FVIII inhibitor formation in LV-F8BDD iv injected F8null mice. A The VCNs in blood cells were detected by genomic DNA qPCR in LV-treated F8null mice over time on days 7, 15, 30, 45, 60, 120 and 180 (n = 3). B The VCNs in the mouse organs including heart, lung, liver, spleen and kidney of the LV-treated F8null mice on day 120 (n = 3). C Determination of anti-FVIII IgG levels by ELISA in the LV-treated F8null mice. The plasma of LV-treated mice was collected 60 days after iv injection and diluted at 1:200 to determine anti-FVIII IgG levels (n = 3). D Analysis of inhibitor titer kinetics using plasma from LV-trated F8null mice over time on days 7, 15, 30, 45, 60, 120 and 180 (n = 3). The inhibitor titer was determined based on a modified Bethesda unit (BU) assay; * D15 and D120 of VEC vs. Gp, * D60 of EF1α vs. VEC, * D60, D120 and D180 of VEC vs. ITGA, ** D120 and D180 of EF1α vs. VEC, * D180 of EF1α vs. Gp. The differences in characteristics between groups were analyzed using the one way Welch ANOVA tests with Turkey post hoc tests (D) or Games-Howell post hoc tests (B–D); *p < 0.05, **p < 0.01, ***p < 0.001